Business Description
Hualan Biological Engineering Inc
NAICS : 541711
SIC : 2836
ISIN : CNE000001JN8
Share Class Description:
SZSE:002007: Class ACompare
Compare
Traded in other countries / regions
002007.China IPO Date
2004-06-25Description
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.89 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.56 | |||||
Interest Coverage | 134.49 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 8.68 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2 | |||||
3-Year EBITDA Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | -5.1 | |||||
3-Year FCF Growth Rate | -5.7 | |||||
3-Year Book Growth Rate | 14.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.31 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.52 | |||||
9-Day RSI | 21.95 | |||||
14-Day RSI | 24.63 | |||||
6-1 Month Momentum % | -16.34 | |||||
12-1 Month Momentum % | -18.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.01 | |||||
Quick Ratio | 3.22 | |||||
Cash Ratio | 1.76 | |||||
Days Inventory | 387.1 | |||||
Days Sales Outstanding | 147.19 | |||||
Days Payable | 47.36 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.89 | |||||
Dividend Payout Ratio | 0.38 | |||||
3-Year Dividend Growth Rate | -9.1 | |||||
Forward Dividend Yield % | 1.89 | |||||
5-Year Yield-on-Cost % | 2.89 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 2.05 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 68.6 | |||||
Operating Margin % | 35.71 | |||||
Net Margin % | 26.52 | |||||
FCF Margin % | 6.59 | |||||
ROE % | 12.64 | |||||
ROA % | 8.98 | |||||
ROIC % | 14.98 | |||||
ROC (Joel Greenblatt) % | 32.17 | |||||
ROCE % | 14.85 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 20.34 | |||||
PE Ratio without NRI | 19.5 | |||||
Shiller PE Ratio | 24.6 | |||||
Price-to-Owner-Earnings | 34 | |||||
PEG Ratio | 3.68 | |||||
PS Ratio | 5.4 | |||||
PB Ratio | 2.44 | |||||
Price-to-Tangible-Book | 2.51 | |||||
Price-to-Free-Cash-Flow | 81.99 | |||||
Price-to-Operating-Cash-Flow | 27.56 | |||||
EV-to-EBIT | 13.13 | |||||
EV-to-Forward-EBIT | 16.23 | |||||
EV-to-EBITDA | 13.13 | |||||
EV-to-Forward-EBITDA | 14.54 | |||||
EV-to-Revenue | 4.92 | |||||
EV-to-Forward-Revenue | 5.72 | |||||
EV-to-FCF | 74.22 | |||||
Price-to-Projected-FCF | 1.72 | |||||
Price-to-DCF (Earnings Based) | 1.05 | |||||
Price-to-DCF (FCF Based) | 3.95 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
Price-to-Graham-Number | 1.48 | |||||
Price-to-Net-Current-Asset-Value | 5.44 | |||||
Earnings Yield (Greenblatt) % | 7.62 | |||||
FCF Yield % | 1.22 | |||||
Forward Rate of Return (Yacktman) % | 2.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hualan Biological Engineering Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 5,248.519 | ||
EPS (TTM) (Â¥) | 0.762 | ||
Beta | 1.56 | ||
Volatility % | 31.26 | ||
14-Day RSI | 24.63 | ||
14-Day ATR (Â¥) | 0.435035 | ||
20-Day SMA (Â¥) | 16.8785 | ||
12-1 Month Momentum % | -18.92 | ||
52-Week Range (Â¥) | 15.45 - 24.55 | ||
Shares Outstanding (Mil) | 1,828.78 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Hualan Biological Engineering Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Hualan Biological Engineering Inc Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Hualan Biological Engineering Inc Frequently Asked Questions
What is Hualan Biological Engineering Inc(SZSE:002007)'s stock price today?
The current price of SZSE:002007 is ¥15.50. The 52 week high of SZSE:002007 is ¥24.55 and 52 week low is ¥15.45.
When is next earnings date of Hualan Biological Engineering Inc(SZSE:002007)?
The next earnings date of Hualan Biological Engineering Inc(SZSE:002007) is .
Does Hualan Biological Engineering Inc(SZSE:002007) pay dividends? If so, how much?
The Dividend Yield %  of Hualan Biological Engineering Inc(SZSE:002007) is 1.89% (As of Today), Highest Dividend Payout Ratio of Hualan Biological Engineering Inc(SZSE:002007) was 0.69. The lowest was 0.28. And the median was 0.44. The  Forward Dividend Yield % of Hualan Biological Engineering Inc(SZSE:002007) is 1.89%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |